Best Fit Profiles
- physician-supervised metabolic risk reduction
Insulin sensitivity and metabolic aging support
Metformin
Landmark and long-term follow-up trials show durable diabetes-prevention benefits, while longevity use remains clinician-guided.
Evidence Level A
Evidence and Risk Labels
Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.
See full scoring guideClinical Snapshot
- Effect Size
- Meaningful glycemic and weight-related improvement in insulin-resistant populations
- Safety
- Needs Monitoring
Prescription medication requiring clinician oversight and renal function monitoring.
Research Dosing
This reflects common ranges and protocols used in published studies, not personal medical advice.
- Typical Daily Dose
- 500-2000 mg (often extended-release, individualized)
- Timing
- With meals to improve GI tolerance
- Protocol Duration in Studies
- Longitudinal, with periodic lab reassessment
Dose and escalation schedule should be individualized to tolerability, kidney function, and treatment goals.